✦ LIBER ✦

6509 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)

✍ Scribed by Sawaki, A.; Yamaguchi, K.; Nabeya, Y.; Sakai, Y.; Osanai, H.; Denda, T.; Furue, H.; Kurihara, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3501 ORAL Capecitabine/cisplatin vs. con

✍ Y. Kang; W. Kang; D. Shin; J. Chen; J. Xiong; J. Wang; M. Lichinitser; M. Philco 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Capecitabine/cisplatin versus 5-fluorour

✍ Kang, Y.-K.; Kang, W.-K.; Shin, D.-B.; Chen, J.; Xiong, J.; Wang, J.; Lichinitse 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 331 KB

P.40 Oral vinorelbine and gemcitabine (o

✍ Vamvakas, L.; Karampeazis, A.; Agelaki, S.; Agelidou, A.; Kotsakis, A.; Kakolyri 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB